9 Biotechnology Stocks to Sell Now

by Portfolio Grader | August 21, 2013 8:30 am

For the current week, the overall ratings of nine Biotechnology stocks are worse, according to the Portfolio Grader[1] database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK[2]) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Merrimack Pharmaceuticals is a biotechnology company, which is focused on the discovery, development and commercialization of drugs for the treatment of immunological and autoimmune diseases with an initial focus on cancer. In Portfolio Grader’s specific subcategories of Earnings Revisions and Cash Flow, MACK also gets F’s. The stock price has fallen 32.1% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of MACK stock[3].

This week, Durata Therapeutics, Inc. (NASDAQ:DRTX[4]) falls to a D (“sell”), worse than last week’s grade of C (“hold”). The stock gets F’s in Earnings Revisions, Equity, and Cash Flow. To get an in-depth look at DRTX, get Portfolio Grader’s complete analysis of DRTX stock[5].

The rating of Genomic Health, Inc. (NASDAQ:GHDX[6]) slips from a C to a D. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. The stock also gets an F in Earnings Revisions. The stock has a trailing PE Ratio of 804.50. For more information, get Portfolio Grader’s complete analysis of GHDX stock[7].

Acorda Therapeutics, Inc. (NASDAQ:ACOR[8]) is having a tough week. The company’s rating falls from a C to a D. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. To get an in-depth look at ACOR, get Portfolio Grader’s complete analysis of ACOR stock[9].

This week, Amarin Corporation Plc Sponsored ADR’s (NASDAQ:AMRN[10]) rating worsens to a D from the company’s C rating a week ago. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. In Earnings Growth, Earnings Revisions, Equity, and Cash Flow the stock gets F’s. As of Aug. 20, 2013, 12.8% of outstanding Amarin Corporation Plc Sponsored ADR shares were held short. For a full analysis of AMRN stock, visit Portfolio Grader[11].

Exelixis, Inc. (NASDAQ:EXEL[12]) is having a tough week. The company’s rating falls from a D to an F. Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. As of Aug. 20, 2013, 21.6% of outstanding Exelixis, Inc. shares were held short. Shares of the stock have been exchanging at an usually rapid pace, twice the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of EXEL stock[13].

The rating of Trius Therapeutics, Inc. (NASDAQ:TSRX[14]) declines this week from a C to a D. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. For a full analysis of TSRX stock, visit Portfolio Grader[15].

This week, Discovery Laboratories (NASDAQ:DSCO[16]) drops from a C to a D rating. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at DSCO, get Portfolio Grader’s complete analysis of DSCO stock[17].

This week, Achillion Pharmaceuticals, Inc.’s (NASDAQ:ACHN[18]) rating worsens to a D from the company’s C rating a week ago. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also gets an F in Equity. As of Aug. 20, 2013, 14.8% of outstanding Achillion Pharmaceuticals, Inc. shares were held short. For a full analysis of ACHN stock, visit Portfolio Grader[19].

Louis Navellier’s proprietary Portfolio Grader[20] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[21].

Source URL: https://investorplace.com/2013/08/9-biotechnology-stocks-to-sell-now-mack-drtx-ghdx/

---